Patient Name : Ms HUDA FATIMA
DOB/Age/Gender : 33 Y/Female Bill Date : Nov 30, 2023, 12:26 PM
Patient ID / UHID : 6355096/OF6355096 Sample Collected : Nov 30, 2023, 12:26 PM
Referred By : [Link] Bala Sample Received : Nov 30, 2023, 02:46 PM
Sample Type : Whole blood EDTA Report Date : Nov 30, 2023, 03:12 PM
Barcode No : HX659864 Report Status : Final Report
Test Description Value(s) Unit(s) Reference Range
HEMATOLOGY REPORT
Antenatal Care Profile (ANC)- Essential
Complete Blood Count (CBC)
RBC PARAMETERS
Hemoglobin 10.8 g/dL 12.0 - 15.0
Method : colorimetric
RBC Count 4 10^6/µl 3.8 - 4.8
Method : Electrical impedance
PCV 32.5 % 36 - 46
Method : Calculated
MCV 80.7 fl 83 - 101
Method : Calculated
MCH 26.7 pg 27 - 32
Method : Calculated
MCHC 33.1 g/dL 31.5 - 34.5
Method : Calculated
RDW (CV) * 14.8 % 11.6 - 14.0
Method : Calculated
RDW-SD * 42.3 fl 35.1 - 43.9
Method : Calculated
WBC PARAMETERS
TLC 7.3 10^3/µl 4 - 10
Method : Electrical impedance and microscopy
DIFFERENTIAL LEUCOCYTE COUNT
Neutrophils 64 % 40-80
Lymphocytes 28 % 20-40
Monocytes 4 % 2-10
Eosinophils 4 % 1-6
Basophils 0 % <2
Absolute leukocyte counts
Neutrophils. 4.67 10^3/µl 2-7
Lymphocytes. 2.04 10^3/µl 1-3
Monocytes. 0.29 10^3/µl 0.2 - 1.0
Eosinophils. 0.29 10^3/µl 0.02 - 0.5
Basophils. 0 10^3/µl 0.02 - 0.5
PLATELET PARAMETERS
Platelet Count 319 10^3/µl 150 - 410
Method : Electrical impedance and microscopy
Mean Platelet Volume (MPV) * 9.5 fL 9.3 - 12.1
(*) Parameter(s) are outside the scope of tests recognized under the NABL M(EL)T Scheme.
Booking Centre :- REDCLIFFE LABS BATLA HOUSE, Jamia Nagar
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., MCD. no.48/3, Ground Floor & Basement Moolraj Building, Main Market Yusuf
Sarai, New Delhi-110016
Page 1 of 10
Patient Name : Ms HUDA FATIMA
DOB/Age/Gender : 33 Y/Female Bill Date : Nov 30, 2023, 12:26 PM
Patient ID / UHID : 6355096/OF6355096 Sample Collected : Nov 30, 2023, 12:26 PM
Referred By : [Link] Bala Sample Received : Nov 30, 2023, 02:46 PM
Sample Type : Whole blood EDTA Report Date : Nov 30, 2023, 03:12 PM
Barcode No : HX659864 Report Status : Final Report
Test Description Value(s) Unit(s) Reference Range
Method : Calculated
PCT * 0.3 % 0.17 - 0.32
Method : Calculated
PDW * 10.6 fL 8.3 - 25.0
Method : Calculated
P-LCR * 22.7 % 18 - 50
Method : Calculated
P-LCC * 72 % 44 - 140
Method : Calculated
Mentzer Index * 20.18
Interpretation:
CBC provides information about red cells, white cells and platelets. Results are useful in the diagnosis of anemia, infections, leukemias, clotting
disorders and many other medical conditions.
(*) Parameter(s) are outside the scope of tests recognized under the NABL M(EL)T Scheme.
Booking Centre :- REDCLIFFE LABS BATLA HOUSE, Jamia Nagar
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., MCD. no.48/3, Ground Floor & Basement Moolraj Building, Main Market Yusuf
Sarai, New Delhi-110016
Page 2 of 10
Patient Name : Ms HUDA FATIMA
DOB/Age/Gender : 33 Y/Female Bill Date : Nov 30, 2023, 12:26 PM
Patient ID / UHID : 6355096/OF6355096 Sample Collected : Nov 30, 2023, 12:26 PM
Referred By : [Link] Bala Sample Received : Nov 30, 2023, 02:46 PM
Sample Type : Whole blood EDTA Report Date : Nov 30, 2023, 03:58 PM
Barcode No : HX659864 Report Status : Final Report
Test Description Value(s) Unit(s) Reference Range
HEMATOLOGY REPORT
Antenatal Care Profile (ANC)- Essential
Erythrocyte Sedimentation Rate (ESR)
ESR - Erythrocyte Sedimentation Rate 31 mm/hr 0 - 12
Method : MODIFIED WESTERGREN
Interpretation:
ESR is also known as Erythrocyte Sedimentation Rate. An ESR test is used to assess inflammation in the body. Many conditions can cause an
abnormal ESR, so an ESR test is typically used with other tests to diagnose and monitor different diseases. An elevated ESR may occur in
inflammatory conditions including infection, rheumatoid arthritis ,systemic vasculitis, anemia, multiple myeloma , etc. Low levels are typically
seen in congestive heart failure, polycythemia ,sickle cell anemia, hypo fibrinogenemia , etc.
AGE MALE FEMALE
1 DAY 0-12 0-12
2 - 7 DAYS 0-4 0-4
8 - 14 DAYS 0-17 0-17
15 DAYS - 17 YEARS 0-20 0-20
18 - 50 YEARS 0-10 0-12
51- 60 YEARS 0-12 0-19
61 - 70 YEARS 0-14 0-20
71 - 100 YEARS 0-30 0-35
Reference- Dacie and lewis practical hematology
(*) Parameter(s) are outside the scope of tests recognized under the NABL M(EL)T Scheme.
Booking Centre :- REDCLIFFE LABS BATLA HOUSE, Jamia Nagar
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., MCD. no.48/3, Ground Floor & Basement Moolraj Building, Main Market Yusuf
Sarai, New Delhi-110016
Page 3 of 10
Patient Name : Ms HUDA FATIMA
DOB/Age/Gender : 33 Y/Female Bill Date : Nov 30, 2023, 12:26 PM
Patient ID / UHID : 6355096/OF6355096 Sample Collected : Nov 30, 2023, 12:26 PM
Referred By : [Link] Bala Sample Received : Nov 30, 2023, 02:46 PM
Sample Type : Whole blood EDTA Report Date : Nov 30, 2023, 06:42 PM
Barcode No : HX659864 Report Status : Final Report
Test Description Value(s) Unit(s) Reference Range
HEMATOLOGY REPORT
Antenatal Care Profile (ANC)- Essential
Blood Group ABO & Rh Typing
Blood Group O
Rh Factor Positive
(*) Parameter(s) are outside the scope of tests recognized under the NABL M(EL)T Scheme.
Booking Centre :- REDCLIFFE LABS BATLA HOUSE, Jamia Nagar
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., MCD. no.48/3, Ground Floor & Basement Moolraj Building, Main Market Yusuf
Sarai, New Delhi-110016
Page 4 of 10
Patient Name : Ms HUDA FATIMA
DOB/Age/Gender : 33 Y/Female Bill Date : Nov 30, 2023, 12:26 PM
Patient ID / UHID : 6355096/OF6355096 Sample Collected : Nov 30, 2023, 12:26 PM
Referred By : [Link] Bala Sample Received : Nov 30, 2023, 02:46 PM
Sample Type : Fluoride Plasma Report Date : Nov 30, 2023, 07:18 PM
Barcode No : ZA564837 Report Status : Final Report
Test Description Value(s) Unit(s) Reference Range
BIOCHEMISTRY REPORT
Antenatal Care Profile (ANC)- Essential
Glucose Random (BSR)
Glucose Random 77.7 mg/dL 70 - 140
Method : (Fluoride Plasma-R,Hexokinase)
Interpretation:
[Link] known as Casual plasma glucose .
[Link] can be taken anytime during the day regardless of eating time.
[Link] blood glucose level of equal to or more than 200mg/dl is indicative of Diabetes mellitus.
Source: ADA Guidelines
(*) Parameter(s) are outside the scope of tests recognized under the NABL M(EL)T Scheme.
Booking Centre :- REDCLIFFE LABS BATLA HOUSE, Jamia Nagar
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., MCD. no.48/3, Ground Floor & Basement Moolraj Building, Main Market Yusuf
Sarai, New Delhi-110016
Page 5 of 10
Patient Name : Ms HUDA FATIMA
DOB/Age/Gender : 33 Y/Female Bill Date : Nov 30, 2023, 12:26 PM
Patient ID / UHID : 6355096/OF6355096 Sample Collected : Nov 30, 2023, 12:26 PM
Referred By : [Link] Bala Sample Received : Nov 30, 2023, 02:46 PM
Sample Type : Serum Report Date : Nov 30, 2023, 05:16 PM
Barcode No : ZA564838 Report Status : Final Report
Test Description Value(s) Unit(s) Reference Range
BIOCHEMISTRY REPORT
Antenatal Care Profile (ANC)- Essential
TSH 3rd Generation
THYROID STIMULATING HORMONE (Ultrasensitive) 0.573 mIU/L 0.54 - 5.30
Method : CMIA
Interpretation:
Pregnancy Reference ranges TSH
1 st Trimester 0.1 - 2.5
2 ed Trimester 0.2 - 3.0
3 rd Trimester 0.3 - 3.0
TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a minimum between 6-10 pm . The variation is of
the order of 50% . hence time of the day has influence on the measured serum TSH concentrations.
Primary malfunction of the thyroid gland may result in excessive (hyper) or below normal (hypo) release of T3 or T4. In addition as TSH directly
affects thyroid function, malfunction of the pituitary or the hypo - thalamus influences the thyroid gland activity. Disease in any portion of the
thyroid-pitutary-hypothala- mus system may influence the levels of T3 and T4 in the blood. In primary hypothyroidism, TSH levels are
significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels may be low. In addition, in the Euthyroid Sick Syndrome,
multiple alterations in serum thyroid function test findings have been recognized in patients with a wide variety of non-thyroidal illnesses (NTI)
without evidence of preexisting thyroid or hypothalami c-pitutary diseases.
Thyroid Binding Globulin (TBG) concentrations remain relatively constant in healthy individuals. However, pregnancy, excess estrogen,
androgen, antibiotics, steroids and glucocorticoids are known to alter TBG levels and may cause false thyroid values for Total T3 and T4 tests.
(*) Parameter(s) are outside the scope of tests recognized under the NABL M(EL)T Scheme.
Booking Centre :- REDCLIFFE LABS BATLA HOUSE, Jamia Nagar
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., MCD. no.48/3, Ground Floor & Basement Moolraj Building, Main Market Yusuf
Sarai, New Delhi-110016
Page 6 of 10
Patient Name : Ms HUDA FATIMA
DOB/Age/Gender : 33 Y/Female Bill Date : Nov 30, 2023, 12:26 PM
Patient ID / UHID : 6355096/OF6355096 Sample Collected : Nov 30, 2023, 12:26 PM
Referred By : [Link] Bala Sample Received : Nov 30, 2023, 02:46 PM
Sample Type : Serum Report Date : Nov 30, 2023, 03:57 PM
Barcode No : SI355256 Report Status : Final Report
Test Description Value(s) Unit(s) Reference Range
SEROLOGY AND IMMUNOLOGY REPORT
Antenatal Care Profile (ANC)- Essential
VDRL
VDRL NON REACTIVE - NON REACTIVE
Method : RAPID CHROMATOGRAPHIC IMMUNOASSAY
Interpretation:
RESULTS REMARKS
Indicates presence of IgM & IgG antibodies against Treponemal Pallidum
Reactive
antigens
Non Indicates absence of IgM & IgG antibodies against Treponemal Pallidum
Reactive antigens
Note
1. Positive result indicates ongoing or recent infection and the diagnosis should be confirmed by specific Treponemal tests such as TPHA &
FTA- AbS.
2. The reactivity will vary with Primary (60-86%), Secondary (99%) and Tertiary (98%) stage of Syphilis.
3. False positive results may be observed in patients of Malaria, Hepatitis, Mumps, Leprosy, Infectious Mononucleosis, Rheumatoid Arthritis
and Collagen disease.
4. False negative reaction may be due to processing of sample collected early in the course of disease, immunosuppression and due to
prozone effect.
5. Test conducted on serum.
6. It is a qualitative test.
Uses
To screen for presence of Syphilis infection.
(*) Parameter(s) are outside the scope of tests recognized under the NABL M(EL)T Scheme.
Booking Centre :- REDCLIFFE LABS BATLA HOUSE, Jamia Nagar
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., MCD. no.48/3, Ground Floor & Basement Moolraj Building, Main Market Yusuf
Sarai, New Delhi-110016
Page 7 of 10
Patient Name : Ms HUDA FATIMA
DOB/Age/Gender : 33 Y/Female Bill Date : Nov 30, 2023, 12:26 PM
Patient ID / UHID : 6355096/OF6355096 Sample Collected : Nov 30, 2023, 12:26 PM
Referred By : [Link] Bala Sample Received : Nov 30, 2023, 02:46 PM
Sample Type : Serum Report Date : Nov 30, 2023, 03:57 PM
Barcode No : SI355256 Report Status : Final Report
Test Description Value(s) Unit(s) Reference Range
SEROLOGY AND IMMUNOLOGY REPORT
Antenatal Care Profile (ANC)- Essential
HIV Antibody, Rapid Card
HIV 1 & 2 ANTIBODIES NON REACTIVE - NON REACTIVE
Method : Qualilative immunoassay,rapid card
Interpretation:
RESULTS REMARKS
Reactive A reactive test results indicates antibody detected against HIV-1/2
Non A non reactive test results indicates antibody is not detected against
reactive HIV- 1/2.
NOTE
[Link] is only a screening test. All samples detected reactive must be confirmed by using HIV Western Blot. Therefore for a definitive diagnosis,
the patient’s clinical history, symptomatology as well as serological data, should be considered. The results should be reported only after
complying with above procedure.
[Link] samples show cross reactivity fir HIV [Link] factors are found to cause false positive HIV antibody test results:
naturally occurring antibodies, Passive immunization, Leprosy, Renal Disorders, Tuberculosis, Myco-bacterium avium, Herpes simplex,
Hypergammaglobulinemia, Malignant neoplasms, Rheumatoid ar thritis, Tetanus vaccination, Autoimmune diseases, Blood Transfusion, Multiple
myeloma, Haemophelia, Heat treated specimens, Lipemic serum, Anti-nuclear antibodies, T-cell leukocyte antigen antibodies, Epstein Barr virus,
HLA antibodies and other retroviruses.
[Link] negative results may occur during the window period and during the end stage of the disease.
(*) Parameter(s) are outside the scope of tests recognized under the NABL M(EL)T Scheme.
Booking Centre :- REDCLIFFE LABS BATLA HOUSE, Jamia Nagar
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., MCD. no.48/3, Ground Floor & Basement Moolraj Building, Main Market Yusuf
Sarai, New Delhi-110016
Page 8 of 10
Patient Name : Ms HUDA FATIMA
DOB/Age/Gender : 33 Y/Female Bill Date : Nov 30, 2023, 12:26 PM
Patient ID / UHID : 6355096/OF6355096 Sample Collected : Nov 30, 2023, 12:26 PM
Referred By : [Link] Bala Sample Received : Nov 30, 2023, 02:46 PM
Sample Type : Serum Report Date : Nov 30, 2023, 03:57 PM
Barcode No : SI355256 Report Status : Final Report
Test Description Value(s) Unit(s) Reference Range
SEROLOGY AND IMMUNOLOGY REPORT
Antenatal Care Profile (ANC)- Essential
Hepatitis C Antibody (HCV), Rapid Card
HEPATITIS C ANTIBODY (Anti-HCV) NON REACTIVE NON REACTIVE
Method : Qualitative immunoassay,rapid card
Interpretation:
RESULTS REMARKS
Reactive Reactive test result indicates presence of Hepatitis C virus infection
Non Non Reactive test result indicates absence of Hepatitis C virus
Reactive infection
NOTE
[Link] 4TH Generation HCV TRI-DOT detects anti-HCV in human serum or plasma and is only a screening test. All reactive samples should be
confirmed by supplemental assays like RIBA .Therefore for a definitive diagnosis, the patient's clinical history ,symptomatalogy as well as
serological data, should be considered. The results should be reported only after complying with above procedure.
2.A non reactive-results does not exclude the possibility of exposure to or infection with HCV.
[Link] false results may occur due to non-specefic binding of the sample to the membrane.
[Link] presence of anti-HCV does not imply a HepatitisC infection but may be indicative of recent and /or past infection By HCV.
[Link] with auto-immune liver diseases may show falsely reactive results.
6. False positive results may be observed in patients receiving mouse monoclonal antibodies, on heparin therapy, on biotin supplements for
diagnosis or therapy or presence of heterophilic antibodies in serum.
5. False negative reaction may be due to processing of sample collected early in the course of disease, Prozone phenomenon, Immunosuppression
& Immuno-incompetence.
Uses ꞏ
To diagnose suspected HCV infection in risk group.
Prenatal Screening of pregnant women and pre surgical/interventional procedures work up.
(*) Parameter(s) are outside the scope of tests recognized under the NABL M(EL)T Scheme.
Booking Centre :- REDCLIFFE LABS BATLA HOUSE, Jamia Nagar
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., MCD. no.48/3, Ground Floor & Basement Moolraj Building, Main Market Yusuf
Sarai, New Delhi-110016
Page 9 of 10
Patient Name : Ms HUDA FATIMA
DOB/Age/Gender : 33 Y/Female Bill Date : Nov 30, 2023, 12:26 PM
Patient ID / UHID : 6355096/OF6355096 Sample Collected : Nov 30, 2023, 12:26 PM
Referred By : [Link] Bala Sample Received : Nov 30, 2023, 02:46 PM
Sample Type : Serum Report Date : Nov 30, 2023, 03:57 PM
Barcode No : SI355256 Report Status : Final Report
Test Description Value(s) Unit(s) Reference Range
SEROLOGY AND IMMUNOLOGY REPORT
Antenatal Care Profile (ANC)- Essential
Hepatitis B Surface Antigen (HBsAg), Rapid Card
HEPATITIS B SURFACE ANTIGEN (HBsAg) NON REACTIVE NON REACTIVE
Method : Qualitative immunoassay,rapid card
Interpretation:
RESULTS REMARKS
Reactive The sample is Reactive for HBsAg
Non Reactive The sample is Non Reactive for HBsAg
Note
[Link] is only a Screening test. All reactive results should be confirmed by confirmatory test. Therefore for a definitive diagnosis, the patient's
clinical history ,symptomatalogy as well as serological data, should be considered. The results should be reported only after complying with above
procedure.
2. Additional follow up testing using available clinical methods (along with repeat HBsAg rapid card test) is required, if the test is Non reactive
with persisting clinical symptoms
3. False positive results may be observed in patients receiving mouse monoclonal antibodies, on heparin therapy, on biotin supplements for
diagnosis or therapy, presence of heterophilic antibodies in serum or after HBV vaccination for transient period of time.
4. False negative reaction may be due to processing of sample collected early in the course of disease or presence of mutant forms of HBsAg.
(*) Parameter(s) are outside the scope of tests recognized under the NABL M(EL)T Scheme.
Booking Centre :- REDCLIFFE LABS BATLA HOUSE, Jamia Nagar
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., MCD. no.48/3, Ground Floor & Basement Moolraj Building, Main Market Yusuf
Sarai, New Delhi-110016
Page 10 of 10
Terms and Conditions of Reporting
1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the
referring physician or other qualified medical professionals possessing a comprehensive understanding of
reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any
interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from
such interpretation.
2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name
or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her
representation at the point of generation of said specimen / sample. It is hereby clarified that the reports
furnished are restricted solely to the given specimen only.
3. It is to be noted that variations in results may occur between different laboratories and over time, even for the
same parameter for the same Customer. The assays are performed and conducted in accordance with standard
procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s)
used, as well as the quality of the received specimen.
4. This report shall not be deemed valid or admissible for any medico-legal purposes.
5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test
finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or
fasting. This list of factors is only representative and not exhaustive.
